Novavax, Gavi in Purchase Agreement for COVID Vaccine for COVAX Facility

 

• Novavax to deliver 350 million doses beginning Q3 2021
• 1.1 billion doses of Novavax vaccine to be available to countries participating in COVAX
• Serum Institute of India to provide balance of doses for LMICs
• Underscores commitment to global equitable access to Novavax vaccine

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has finalized an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi) for supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to manufacture and distribute 350 million doses of NVX-CoV2373 to countries participating under the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. Under a separate purchase agreement with Gavi, the Serum Institute of India (Serum Institute) is expected to manufacture and deliver the balance of the 1.1 billion doses of Novavax' vaccine.

https://www.newswire.ca/news-releases/novavax-and-gavi-execute-advance-purchase-agreement-for-covid-19-vaccine-for-covax-facility-867138418.html